Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Abramson Cancer Center at Penn Medicine
Memorial Sloan Kettering Cancer Center
Prescient Therapeutics, Ltd.
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
University of Pittsburgh
Fondazione Italiana Linfomi - ETS
Fondazione Italiana Linfomi - ETS
Kasr El Aini Hospital
Institute of Hematology & Blood Diseases Hospital, China
Soligenix
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
Stanford University
National Cancer Institute (NCI)
City of Hope Medical Center
Assistance Publique - Hôpitaux de Paris
Mayo Clinic
M.D. Anderson Cancer Center
Kyowa Kirin Co., Ltd.
Columbia University
SciTech Development, Inc.
Kyowa Kirin Co., Ltd.
City of Hope Medical Center
City of Hope Medical Center
Soligenix
Leiden University Medical Center
University of Alabama at Birmingham
Icahn School of Medicine at Mount Sinai
Barbara Ann Karmanos Cancer Institute
Stanford University
AHS Cancer Control Alberta
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
Mayo Clinic
Memorial Sloan Kettering Cancer Center
University of California, Davis
Bristol-Myers Squibb
Thomas Jefferson University